Gary McDaniel, MD
Interventional Pain Medicine · Baton Rouge, LANPI 1407198286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 353 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 60.8% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $2,445 and has fallen 61.7% since, to $936 in 2025.
Across 353 payments — averaging $25.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Boston Scientific$701
- Collegium Pharmaceutical, Inc.$306
- Medtronic$266
- Valinor Pharma, LLC$215
- Lundbeck LLC$194
- plus $2K from 26 others
What the payments were for
- Travel & lodging$7739%
- Food & beverage$8,12791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 180 | $5,408 |
| Boston Scientific | 40 | $701 |
| Collegium Pharmaceutical, Inc. | 15 | $306 |
| Medtronic(2 entities) | 8 | $266 |
| Valinor Pharma, LLC | 17 | $215 |
| Lundbeck LLC | 10 | $194 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $188 |
| Si-bone, Inc. | 3 | $175 |
| Nevro Corp. | 8 | $158 |
| Virtus Pharmaceuticals LLC | 9 | $147 |
| AbbVie | 8 | $143 |
| Scilex Pharmaceuticals Inc. | 6 | $116 |
| Biotronik NRO, Inc. | 3 | $115 |
| Azurity Pharmaceuticals, Inc. | 5 | $111 |
| Saluda Medical Americas, Inc. | 1 | $82 |
| Avanos Medical | 2 | $69 |
| Arbor Pharmaceuticals, Inc. | 4 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $62 |
| Amgen | 3 | $54 |
| Stryker | 2 | $44 |
| IBSA Pharma Inc. | 2 | $38 |
| Pfizer | 2 | $37 |
| SPR Therapeutics, Inc | 1 | $29 |
| Relievant Medsystems, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Spinal Simplicity, LLC | 1 | $24 |
| Globus Medical | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Bioventus LLC | 1 | $18 |
| Vertex | 1 | $17 |
| Vertos Medical, Inc. | 1 | $12 |
| Nalu Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$1,721
- Proclaim Family of SCS IPGs$803
- Proclaim IPG$736
- ETERNA$267
- INTELLIS$110
How this compares
$8,900 in reported general payments places this provider in the 70th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,930 | $31,346 |
| RelistorMethylnaltrexone Bromide | 16 | $30,545 |
| MovantikNaloxegol Oxalate | 38 | $16,934 |
| Gabapentin | 1,531 | $15,604 |
| OxycontinOxycodone Hcl | 21 | $14,435 |
| BelbucaBuprenorphine Hcl | 14 | $11,127 |
| SavellaMilnacipran Hcl | 11 | $8,830 |
| Pregabalin | 683 | $7,776 |
| Lidocaine | 61 | $7,324 |
| Diclofenac Sodium | 625 | $7,130 |
| Celecoxib | 272 | $4,740 |
| Tramadol Hcl | 802 | $4,641 |
| Tramadol Hcl ErTramadol Hcl | 79 | $4,628 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 245 | $4,244 |
| Tizanidine Hcl | 761 | $3,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $188 | $30,54516 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $306 | $11,12714 claims |
| AbbVieSavella | $143 | $8,83011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Baton Rouge
- Adam CarinciBaton Rouge$17K
- Jihad JihaBaton Rouge$17K
- Kelly BoussertBaton Rouge$9K
- John BraswellBaton Rouge$8K
- Sean GrahamBaton Rouge$5K
- John CrosbyBaton Rouge$5K
- Alpesh PatelBaton Rouge$4K
- Joseph TurnipseedBaton Rouge$4K
- Allison WalkerBaton Rouge$2K
- John BurdineBaton Rouge$177
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.